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Left ventricular outﬂow tract obstruction
Tako-tsubo cardiomyopathySome patients with tako-tsubo cardiomyopathy (TCM) develop
cardiogenic shock or cardiac rupture due to left ventricular outﬂow
tract (LVOT) obstruction [1–4]. LVOT obstruction is reported to occur
in 10–25% of patients with TCM [5,6]. The exact mechanism of TCM is
unknown. The trigger is frequently, but not always, an intense
emotional or physical stress. The pathogenesis is not well under-
stood but a number of theories exist; catecholamine drive, oxidative
stress, estrogen deﬁciency, transient coronary artery spasm, or
genetic predisposition. Catecholamine concentrates such as epi-
nephrine and nor-epinephrine levels have been noted to be high
during the acute phase of TCM, and excessive catecholamine levels
appear to have a major role in the pathology of this disorder [4,7].
A study showed that out of 136 consecutive patients with TCM,
13 patients developed dynamic obstruction to LVOT (gradients,
54  48 mmHg) due to systolic anterior motion (SAM) of the mitral
valve and mitral–septal contact, and in seven patients, following the
intravenous administration of inotropic agents for hypotension [3]. A
systematic analysis of the literature demonstrated LVOT obstruction
in 25% of patients with TCM, all of whom presented with septal bulge
associated with SAM of the mitral valve and mitral regurgitation. This
morphology of the ventricular septum is mostly present in elderly
patients and appears to be an important factor for LVOT obstruction in
TCM [7,8].
LVOT obstruction is also a common characteristic of hypertro-
phic cardiomyopathy (HCM). Up to one-third of patients with HCM
will have obstruction under basal (resting) conditions (deﬁned as
gradients 30 mmHg). Another one-third or more of patients will
have labile, physiologically provoked gradients (<30 mmHg at rest
and 30 mmHg with physiologic provocation) [9,10].
Outﬂow obstruction usually occurs in HCM by virtue of mitral
valve SAM and mitral–septal contact. In HCM, the mitral leaﬂets
are anteriorly positioned with extension of leaﬂet tips past the
point of coaptation into the outﬂow tract. The papillary muscles
are anteriorly malpositioned and can be inserted directly onto the
mitral leaﬂet. These geometric papillary muscle changes, inDOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.01.005
http://dx.doi.org/10.1016/j.jccase.2015.03.003
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightcombination with mitral leaﬂet elongation, lead to less posterior
leaﬂet tethering and thus provide sufﬁcient leaﬂet mobility to
result in SAM [10–12]. Although the mechanism of the outﬂow
tract gradient in HCM was initially thought to be caused by systolic
contraction of the hypertrophied basal ventricular septum
encroaching on the LVOT, most recent studies have demonstrated
that given the mitral anatomy in HCM, the predominant
mechanism of SAM is related to drag on the mitral valve leaﬂet,
generated by blood ﬂow acceleration across the septum during
ventricular systole, ‘pushing’ the leaﬂets into the LVOT [10–12].
As opposed to a ﬁxed stenosis in aortic stenosis, subvalvular
obstruction is dynamic and ﬂuctuates signiﬁcantly based upon
changes in numerous clinical factors, including ﬂuctuations in
volume status, autonomic nervous activity, diurnal variation,
pharmacotherapy, exercise, and physical position during assess-
ment [10–12].
To decrease pressure gradient of LVOT obstruction in TCM,
treatment with a b-blocker, a calcium channel blocker such as
verapamil or diltiazem, or an a-adrenoceptor agonist such as
phenylephrine will be usually considered. Volume expansion will
be also considered. These treatments will be useful in preventing
acute complications such as cardiogenic shock due to LVOT
obstruction, ventricular arrhythmias, or ventricular rupture [1,2].
The use of b-blockers for LVOT obstruction in TCM has been
speciﬁcally advocated due to the possible abnormal response to
excessive catecholamines. Administration of b-blockers would be
reasonable when coronary spasm is not suspected on initial
presentation, because excess catecholamines may be involved in
the pathophysiology. It is necessary to take care of worsening heart
failure or coronary spasm after initiation of therapy [1].
In HCM patients with LVOT obstruction who develop symp-
toms, b-blockers are the mainstay of pharmacologic therapy and
the ﬁrst-line agents because of their negative inotropic effects and
their ability to attenuate adrenergic-induced tachycardia [10]. Al-
though verapamil can also be considered, caution should be
exercised in its administration to patients with marked resting
gradients and advanced heart failure. Left ventricular (LV) ﬁlling
can be improved by these drugs, although basal gradients are not
usually mitigated signiﬁcantly [13]. b-Blockers are most effective
in blunting gradients provoked with exercise. Disopyramide is the
most reliable drug for reducing outﬂow gradients at rest in HCM,
although long-term use may be limited by parasympathetic side
effects [13].
Hamada et al. proposed to use cibenzoline for the reduction of
LVOT gradient in HCM. Unlike disopyramide, cibenzoline has little
anticholinergic activity; therefore, this drug can be easily adapteds reserved.
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gradient, cibenzoline can improve LV diastolic dysfunction, and
induce regression of LV hypertrophy in patients with HCM [14]. A
decrease in intracellular Ca2+ concentration through the activation
of the Na+/Ca2+ exchanger associated with cibenzoline therapy is
likely to be closely related with the improvement in HCM-related
disorders. It is possible that cibenzoline can prevent the progres-
sion from typical HCM to end-stage heart failure. One factor for the
reduction of pressure gradient may be a suppression of LV over-
contraction, and the other important mechanism may be LV
reverse remodeling by cibenzoline therapy [14].
In this issue, Tomofuji et al. [15] report a case with TCM
demonstrating a LVOT pressure gradient with 72 mmHg and
considered to be a high risk for cardiac rupture. b-Blockers were
contraindicated for the patient because of bronchial asthma.
Intravenous cibenzoline administration resulted in successful
attenuation of the patient’s LVOT obstruction. The present case
suggests that cibenzoline might be effective for the treatment of
LVOT obstruction in TCM, especially in those contraindicated for b-
blocker therapy.
b-Blockers are the ﬁrst-line drugs for the treatment of LVOT
obstruction in TCM and HCM. In case b-blockers are contra-
indicated due to bronchial asthma or coronary artery spasm or b-
blockers are ineffective, other drugs such as verapamil for both
conditions or disopyramide for HCM will be considered. Cibenzo-
line is an alternative drug for HCM, and the effects and safety have
been well established. Tomofuji et al. have shown that cibenzoline
is also effective for LVOT obstruction in TCM when b-blockers or
other drugs are contraindicated or ineffective [15].
The mechanisms of LVOT obstruction in TCM and HCM have
similarity but are not identical. LVOT obstruction in TCM is acute
and transient, and sometimes life threatening. LVOT obstruction in
HCM is chronic, dynamic, and contributes to the debilitating heart
failure-related symptoms that may occur in HCM and is also a
determinant of outcome. Although more clinical experience will be
required, cibenzoline could be a new option for clinical manage-
ment of LVOT obstruction in TCM.
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